Objectives: To evaluate the short-and long-term clinical outcomes of RA in CTO coronary intervention.
guided re-entry technique for suitable patients in case both antegrade and retrograde approaches failed. Following the crossing of the CTO lesion by guidewire, the smallest balloon catheter (1.0-1.25 mm) was introduced for lesion dilation. When even the smallest balloon catheter was unable to cross the occlusive lesion, we tried several methods to increase support of the guiding catheter, including changing guiding catheter and buddy wire technique, anchoring balloon catheter technique and child in mother catheter method, or Tornus microcatheter. If all of these methods failed, almost always due to heavy calcification, the particular CTO lesion will be defined as a resistant CTO lesion, and RA treatment would be attempted after confirmation of the guidewire in the true lumen by contralateral angiography. Over-the-wire microcatheters were advanced as far as possible adjacent to the CTO lesions for the exchange of first-pass guidewire with rotawire, which could cross the CTO lesions with 100% success rates. RA (Boston Scientific, Natick, MA) was then performed by standard procedure. The RA was always started with a burr size of 1.25 mm with a burr speed of 160 000-185 000 rpm. The CTO lesions were then ablated by RA burr and polished with a final round without loss of burr speed. Sometimes a larger burr (1.50-1.75 mm) was used for adequate debulking of the calcified CTO lesion. A cocktail solution, composed of unfractionated heparin (5000 U), isoptin (2.5 mg), and isoket (5 mg) in 500 mL 5% glucose water, was infused continuously during the debulking procedure. Following successful RA, we routinely used IVUS to evaluate the thickness of calcification and vessel size, and sometimes the larger burr was used for adequate debulking of calcified plaque. Then, the CTO were obtained at the end of the procedure. Dual antiplatelets were started after the procedure, and all patients received Aspirin (100 mg/d) indefinitely and Clopidogrel (300 mg loading dose, and 75 mg maintenance per day) for at least 3 months (bare metal stent (BMS)) or 12 months (drug-eluting stent, DES). Medications for the treatment of angina pectoris (calcium channel blockers, beta-blockers, and nitrates) were continued. The operation records and medical charts were thoroughly reviewed, and all demographic and procedural variables were recorded in a data collection sheet.
| Follow-up and study endpoints
All patients were followed up by medical chart review and telephone contact and no patient loss was experienced at follow-up. The endpoints included 1-year cardiovascular (CV) death, 1-year major adverse cardiovascular event (MACE, including ischemia-driven target vessel revascularization (TVR), non-fatal myocardial infarction (MI), and CV death), long-term (more than 4 years) CV death and long-term MACE after index procedure. TVR was defined as restenosis requiring PCI over previously treated lesions. Non-fatal MI was defined as the presence of significant new Q waves in at least 2 electrocardiography leads or of symptoms compatible with MI associated with an increase in creatinine kinase-MB fraction ≥3 times the upper limit of the reference range. CV death was diagnosed as any death with definite CV cause or any death that was not clearly attributed to a non-CV cause. The study protocol was approved by the Institutional Review Board at Taipei-Veterans General Hospital, and all participants provided written informed consent. The principal clinical characteristics of the RA group and the non-RA group are summarized in Table 1 . The mean age of the non-RA group was 66.4 ± 12.8 years, and most of the patients were male (215, 83.0%). Compared to the non-RA group, the patients in the RA group were older (P = 0.028), had more smokers (including past and current; P = 0.015) and tended to have a lower prevalence of hypertension (P = 0.048).
| Statistical analysis
The angiographic characteristics of both groups are listed in Table 2 . We performed 208 antegrade approach of CTO PCIs (73%) and 77 retrograde approach of CTO PCIs (27%), with a similar rate of retrograde approaches in both groups. The CTO lesions in the RA group were always longer and needed longer stents (P = 0.001), with higher J-CTO scores (P < 0.001), and were more frequently associated with the presence of heavy calcification (P < 0.001).
The PCI procedure in the RA group took longer fluoroscopic times (P < 0.001), used more contrast medium volumes (P < 0.001) as well as higher radiation doses (P < 0.001, Table 2 ). Follow-up angiography was carried out in 237 patients (213 patients in the non-RA group and 24 patients in the RA group, P = 0.186, Table 2 ).
| The short-and long-term clinical outcomes
All patients were successfully treated by CTO PCI without major complications, except 1 patient in the RA group who suffered from coronary perforation after RA in treating distal CTO at the right coronary artery, probably resulting from the use of an oversized burr (1.5 mm burr) (success rate: RA group vs non-RA group: 96.2%, vs 89.5%, P = 0.038). This patient underwent emergent surgical intervention and recovered uneventfully after surgery without any other major complications. In the RA group, the 1.25 mm burr was used in 18 patients and the 1.50 mm in eight cases. After RA, all CTO lesions were treated with balloon dilation and stenting with good stent expansion.
The final coronary TIMI flow was similar in both groups, with nearly 100% reaching final TIMI 3 flow (Table 2 ). In particularly, slow-flow/ no-reflow phenomenon was not noted after RA in the RA group.
Regarding the 1-year clinical outcomes, 1-year MACE was observed in 45 patients in the non-RA group and in 1 patient in the RA group (P = 0.038). Although the treatment of RA appeared to be associated with less 1-year MACE, 1-year non-fatal MI, 1-year TLR as well as 1-year CV death (all P < 0.05, Table 3 period, 25 patients (10.8%) died, of which all were classified as CV in origin. The short-term (1-year) and long-term (more than 1 year)
clinical outcomes are summarized in Table 3 , with the clinical outcomes similar to those of the total enrolled population.
4 | DISCUSSION
| Main findings
In this study, we found that RA was needed to recanalize resistant CTO in about 9% (26 patients) of CTO cases, and the use of RA was feasible and safe, and may increase the procedural success rate in these tough CTO lesions with heavy calcification. Furthermore, the treatment of RA was associated with comparable short-and long-term clinical outcomes compared to those not using RA.
| Benefits of successful revascularization of CTO and the strategies of resistant CTO
A successful revascularization of CTO has a significant 10-year survival advantage compared with failed revascularization. 16 Several studies showed the symptomatic and prognostic benefits of successful canalization of the CTO lesions, and they have been shown to improve angina status, survival, and left ventricular systolic function. 5, [16] [17] [18] [19] There are many benefits mentioned above, therefore it is very important to successfully recanalize resistant CTO.
The inability of the balloon catheter and devices to cross the occlusive lesions with heavy calcification accounts for 2-15% of failed CTO recanalization procedures. 14, 20 In this situation, special strategies, such as buddy wire technique, anchoring balloon technique, deep seating of guiding catheter, child in mother guiding catheters might sometimes be helpful. In addition, manual rotation of the Tornus catheter has been reported to be useful for penetration of resistant CTO lesions. 6 However, in most resistant CTOs with heavy calcification, RA is always needed for successful PCI. Fang et al evaluated the | 461 feasibility and safety of the RA and the Tornus catheter, for resistant CTO lesion, and found that RA was associated with significantly shorter procedural durations and higher device success rates compared to the Tornus catheter. In contrast, the 30-day clinical success rate was significantly higher in the RA group compared to the Tornus group (93% vs 72%, P = 0.02) 21 Pagnotta et al also reported the success rate of Tornus in 45% of resistant CTO lesions. 22 Therefore, RA should be the first choice for resistant CTO lesions with heavy calcification. In general, the passing of calcified CTO lesions by rotawire is the first mandatory step for RA, and most interventionists will try to advance the microcatheter (eg, Corsair microcatheter, Ashai, Japan) across the lesion, and exchange the ordinary guidewire with rotawire. However, this step is always impossible in resistant CTO lesions, as no devices are able to pass these calcified CTO lesions. We always advance our microcatheter as far as possible in front of the calcified CTO lesion, and then manipulate the rotawire carefully, and most of the time the rotawire is able to pass the tough lesion, probably through the channel created by previously crossed guidewires. In contrast, the Tornus microcatheter can also be used for the exchange of rotawire.
Although RA might show better debulking effects, previous studies have shown a higher incidence of complications in patients treated by RA and it might account for 22-25.6% of complications. 9,23 Pagnotta et al reported 45 patients with resistant CTO lesions treated with RA, with a 95.5% success rate. They found significantly a higher peri-procedural MI rate (35%) but without cases with coronary perforation after RA. 23 Recently, Azzalini et al also reported the short-and long-term clinical outcomes of the use of RA for the CTO PCI. They used RA to treat balloon failure to cross CTO lesions in 51% of 35 patients, without major complications noted. However, slow-flow/no-reflow was noted in 17% of cases.
Furthermore, their RA procedural success rate was significantly lower compared with the conventional PCI group (77% vs 88%, P = 0.04), while the long-term MACE rate was similar between the RA and conventional group (15% vs 13%, P = 0.70). 24 Our results showed high success rate (96.2%) with low peri-procedural complications (1 case), suggesting that RA might be a safe and effective technique for resistant CTO lesions. Furthermore, our results also suggested that the RA-assisted CTO PCI might be associated with comparable long-term clinical outcomes to those of conventional PCI group. As we routinely confirmed that the rotawire was at least in the distal true lumen by contralateral angiography 
| Limitations
Several limitations of this study need to be addressed. First, this study was a single-center observational study with a limited sample size.
Furthermore, significantly more BMS were used in the conventional CTO PCI group. However, subgroup analysis in our DES group showed the similar results (Table 3) . Second, the angiographic follow-up rate of our population was relatively low, and incomplete angiographic followup related potential bias might have a substantial impact on the longterm clinical outcomes in both groups.
| CONCLUSIONS
RA is a safe and effective treatment for resistant CTO lesions with heavy calcification, with a relatively low peri-procedural complication rate. Furthermore, the use of RA was associated with comparable long-term clinical outcomes compared with conventional groups.
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